The pandemic changed everything in vaccine development, and now the whole world is catching up. Endpoints News senior editor Amber Tong will cover the new world of vaccine research as officials look to vaccinate against viral threats like monkeypox and the Covid variants on timelines that would have been considered impossible just 2 years ago. Tong will also cover the deep changes that are transforming vaccine manufacturing and delivery as governments prime the vaccine R&D pump with billions to support a revolution in fast development. Millions of lives are on the line as viruses now spread faster than ever.
Dr. Adolfo García-Sastre is Professor in the Departments of Microbiology and Medicine, and Director of the Global Health and Emerging Pathogens Institute of Icahn School of Medicine at Mount Sinai in New York, NY. He is also Principal Investigator for the Center for Research on Influenza Pathogenesis and Transmission (CRIPT), one of five NIAID Centers of Excellence for Influenza Research and Response (CEIRR). For the past 30 years, his research interest has been focused on the molecular biology, virus-host interactions, innate immunity and pathogenesis of influenza viruses and several other RNA viruses, as well as on the development of new vaccines and antivirals. He has more than 600 peer-reviewed publications in these areas of research. In 2017, he was elected as a fellow of the Royal Academy of Pharmacy in Spain, and in 2019, he was elected to the National Academy of Sciences.
Dr. Vikram Paradkar received PhD in Chemical & Biochemical Engineering from University of Iowa, USA and has worked in multiple biotechnology product focused companies in USA and India for last 30 years. These include stints at Monsanto Corp, USA; Bayer Biological Products, USA, Wyeth, USA, Reliance Life Sciences, India and last 10 years at Biological E Limited, India. He has worked in various leadership positions related to biotech product and process development, clinical & commercial manufacturing, facility design, qualification & technology transfers. In his current role at Biological E, a large & fully integrated vaccine development and manufacturing company, he provides leadership and oversight to new vaccine development and clinical & commercial manufacturing of a broad portfolio of vaccines from all platform technologies. He led the development of BioE’s COVID19 vaccine CORBEVAX which is an adjuvanted protein sub-unit vaccine and approximately 85 million doses of that vaccine has been administered in India in mainly Pediatric population.
Amber Tong is the senior editor at Endpoints News, where she reports on news and feature stories while keeping an eye on the overall voice and look of the site. Her coverage varies daily but as a Hong Kong native, she is particularly excited about biopharma trends in China. A graduate of Rice University, she has previously written for and edited the Rice Thresher, Houstonia Magazine, Governing Magazine and The Chautauquan Daily. Amber is based in Hong Kong.
Eva Lindskog has a M.Sc. in Chemical Engineering and a PhD in Bioprocess Technology from Royal Institute of Technology, Sweden. She started her career as a scientist in Astra Zeneca and GE Healthcare, focusing on upstream single-use technology. Later, she took on various commercial roles in marketing, product management, business development and general management. In 2017 Eva moved to Switzerland for a position at Lonza. Since 2020 Eva is at Sartorius, currently as Head of Fluid Management Technologies business area. She is a co-editor of the book Biopharmaceutical Processing (Elsevier, 2018).